Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion type Assertion NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_head.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion description "[Previously, we suggested that imatinib incorporation into conventional chemotherapy as an alternative (imatinib interim therapy) might be a useful strategy for bridging the time to allogeneic stem cell transplantation (SCT) for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_provenance.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion evidence source_evidence_literature NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_provenance.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion SIO_000772 15657178 NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_provenance.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion wasDerivedFrom befree-20140225 NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_provenance.
- NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_assertion wasGeneratedBy ECO_0000203 NP651125.RA6JxA2sGDe3f51gt-4NbeeL0GaixK07hRuWz2La-xZk8130_provenance.